Literature DB >> 12372819

Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.

Mark Peek1, Paul Moran, Nerissa Mendoza, Dineli Wickramasinghe, Daniel Kirchhofer.   

Abstract

Hepatocyte growth factor (HGF), the ligand for the receptor tyrosine kinase c-Met, is composed of an alpha-chain containing four Kringle domains (K1-K4) and a serine protease domain-like beta-chain. Receptor activation by HGF is contingent upon prior proteolytic conversion of the secreted inactive single chain form (pro-HGF) into the biologically active two chain form by a single cleavage at the Arg(494)-Val(495) bond. By screening a panel of serine proteases we identified two new HGF activators, plasma kallikrein and coagulation factor XIa (FXIa). The concentrations of kallikrein and FXIa to cleave 50% (EC(50)) of (125)I-labeled pro-HGF during a 4-h period were 10 and 17 nm. Unlike other known activators, both FXIa and kallikrein processed pro-HGF by cleavage at two sites. Using N-terminal sequencing they were identified as the normal cleavage site Arg(494)-Val(495) and the novel site Arg(424)-His(425) located in the K4 domain of the alpha-chain. The identity of this unusual second cleavage site was firmly established by use of the double mutant HGF(R424A/R494E), which was completely resistant to cleavage by kallikrein and FXIa. Experiments with another mutant form, HGF(Arg(494) --> Glu), indicated that cleavage at the K4 site was independent of a prior cleavage at the primary, kinetically preferred Arg(494)-Val(495) site. The cleavage at the K4 site had no obvious consequences on HGF function, because it was fully capable of phosphorylating the c-Met receptor of A549 cells. This may be explained by the disulfide bond network in K4, which holds the cleaved alpha-chain together. In conclusion, the ability of plasma kallikrein and FXIa to activate pro-HGF in vitro raises the possibility that mediators of inflammation and blood coagulation may also regulate processes that involve the HGF/c-Met pathway, such as tissue repair and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372819     DOI: 10.1074/jbc.M209778200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Alternative proteolytic processing of hepatocyte growth factor during wound repair.

Authors:  Nils Buchstein; Daniel Hoffmann; Hans Smola; Sabina Lang; Mats Paulsson; Catherin Niemann; Thomas Krieg; Sabine A Eming
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

2.  An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides.

Authors:  Kyle E Landgraf; Micah Steffek; Clifford Quan; Jeffrey Tom; Christine Yu; Lydia Santell; Henry R Maun; Charles Eigenbrot; Robert A Lazarus
Journal:  Nat Chem Biol       Date:  2014-05-25       Impact factor: 15.040

3.  Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.

Authors:  Daniel Kirchhofer; Michael T Lipari; Lydia Santell; Karen L Billeci; Henry R Maun; Wendy N Sandoval; Paul Moran; John Ridgway; Charles Eigenbrot; Robert A Lazarus
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

4.  Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.

Authors:  Sylvia Herter; Derek E Piper; Wade Aaron; Timothy Gabriele; Gene Cutler; Ping Cao; Ami S Bhatt; Youngchool Choe; Charles S Craik; Nigel Walker; David Meininger; Timothy Hoey; Richard J Austin
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

5.  Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factor.

Authors:  Steven P Grover; Clare M Schmedes; Alyson C Auriemma; Emily Butler; Molly L Parrish; Adam Miszta; Audrey C Cleuren; Mayken Visser; Stefan Heitmeier; Jens J Posma; Henri M Spronk; Silvio Antoniak; Alisa S Wolberg; Rafal Pawlinski; David Gailani; Nigel Mackman
Journal:  Blood Adv       Date:  2020-01-14

6.  Activation of hepatocyte growth factor by urokinase-type plasminogen activator is ionic strength-dependent.

Authors:  Wendy M Mars; Minji Jo; Steven L Gonias
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

7.  Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.

Authors:  Karim Abid; Bertrand Rochat; Paul-Gerhard Lassahn; Reto Stöcklin; Sophie Michalet; Noureddine Brakch; Jean-Francois Aubert; Bilgin Vatansever; Patricia Tella; Ingrid De Meester; Eric Grouzmann
Journal:  J Biol Chem       Date:  2009-07-20       Impact factor: 5.157

Review 8.  Role of plasma kallikrein in diabetes and metabolism.

Authors:  E P Feener; Q Zhou; W Fickweiler
Journal:  Thromb Haemost       Date:  2013-05-16       Impact factor: 5.249

9.  Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration.

Authors:  Thomas H Sisson; Mai-Huong Nguyen; Bi Yu; Margaret L Novak; Richard H Simon; Timothy J Koh
Journal:  Blood       Date:  2009-10-07       Impact factor: 22.113

Review 10.  MET: a critical player in tumorigenesis and therapeutic target.

Authors:  Carrie R Graveel; David Tolbert; George F Vande Woude
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.